John Ruesch
Corporate Officer/Principal presso ASTRIA THERAPEUTICS, INC.
Posizioni attive di John Ruesch
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ASTRIA THERAPEUTICS, INC. | Corporate Officer/Principal | 17/07/2023 | - |
Storia della carriera di John Ruesch
Precedenti posizioni note di John Ruesch
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| SURFACE ONCOLOGY, INC. | Corporate Officer/Principal | - | - |
Formazione di John Ruesch
| Valparaiso University | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
Posizioni
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ASTRIA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- John Ruesch
- Esperienza
